October 30, 2026

Salt Lake City – The US Department of Health and Human Services (HHS) has released an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with notice published in the Federal Register on October 30, 2026.
The Utah Division of Professional Licensing (DOPL) will exercise similar limited enforcement discretion in Utah, in strict accordance with the scope of this HHS interim policy.
DOPL will apply enforcement discretion only when each condition listed in the HHS interim policy is met.
For more information visit, see the Federal Register Notice.